Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ACM.0000000000000776 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Learning About Their Condition: The Gradual Path of Young People With Childhood-Onset Motor Disabilities.
Acta Paediatr
January 2025
Paediatric Neurology and Neurorehabilitation Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Aim: Young people with childhood-onset motor disabilities face unique challenges in understanding and managing their condition. This study explored how they learnt about their condition.
Method: A descriptive qualitative study was conducted in 2023-2024 at a Swiss paediatric neurorehabilitation unit.
Bots in white coats: are large language models the future of patient education? a multi-center cross-sectional analysis.
Int J Surg
January 2025
Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Germany.
Objectives: Every year, around 300 million surgeries are conducted worldwide, with an estimated 4.2 million deaths occurring within 30 days after surgery. Adequate patient education is crucial, but often falls short due to the stress patients experience before surgery.
View Article and Find Full Text PDFThigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With Human Immunodeficiency Virus Type 1: A Substudy of the Phase 3b ATLAS-2M Study.
Clin Infect Dis
January 2025
ViiV Healthcare, Durham, North Carolina, USA.
Background: Cabotegravir + rilpivirine (CAB + RPV) administered via intramuscular gluteal injections is the first complete long-acting regimen for maintaining human immunodeficiency virus type 1 (HIV-1) virologic suppression. We present substudy results on short-term repeat intramuscular CAB + RPV long-acting thigh injections in participants with ≥3 years of experience with gluteal administration during the ATLAS-2M study.
Methods: Substudy phases included screening, thigh injection (day 1-week 16), and return to gluteal injection (week 16-week 24).
Flaxseed powder supplementation in non-alcoholic fatty liver disease: a randomized controlled clinical trial.
Food Funct
January 2025
Lianshui People's Hospital Affiliated to Kangda College of Nanjing Medical University, Huai'an, Jiangsu, 223400, China.
: Non-alcoholic fatty liver disease (NAFLD) has become a growing public health problem worldwide, and dietary interventions have important potential in the prevention and treatment of NAFLD. Moreover, previous animal studies have shown that flaxseed has a good improvement effect in animal NAFLD models. : Assess whether flaxseed powder could improve the liver lipid content in patients with NAFLD.
View Article and Find Full Text PDFPreparation and characterization of tildipirosin-loaded solid lipid nanoparticles for the treatment of intracellular infections.
Biomater Sci
January 2025
School of Chemistry, Chemical Engineering and Life Science, Hubei Key Laboratory of Nanomedicine for Neurodegenerative Diseases, Wuhan University of Technology, 122 Luoshi Road, Wuhan 430070, China.
To enhance the antibacterial efficacy of tildipirosin against (S.A.) infections, optimized solid lipid nanoparticles loaded with tildipirosin (SLN-TD) were developed, using docosanoic acid (DA), octadecanoic acid (OA), hexadecanoic acid (HA), and tetradecanoic acid (TA) as lipid components.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!